Search 

Assist Consultation, Assistance, Service
• Identify Distribution Opportunities, Partners, Joint Ventures
• Guidance for Product Registration (SFDA), Regulatory Issues
• Intellectual Property Assessment
• Develop Successful Business Strategy
• Marketing/Analysis
• Manufacturing/Sourcing
• Investment Advisory

Bioxis, creates biomaterial scaffolds that help regenerate tissues, improve patient outcomes, and provide better healthcare opportunities for doctors. We are focused on developing medical devices based on patented biomaterials technology with potentially accelerated pathways to the aesthetic dermatology market.

Our lead medical device candidate MTI-12 is currently at the pre-clinical stage for aesthetic indications; and our hyaluronic acid-based dermal filler brand, CYTOSIAL, has established into exclusive distribution agreements with distributors in Europe and Asia.

MNC

Calciscon develops and markets diagnostic devices for the assessment of calcification- and cardiovascular risk to improve disease management of kidney patients worldwide. Our flagship product T50 is the only test capable of accurately predicting the prognosis of a kidney patient. Across 30+ peer-reviewed studies, T50 was demonstrated to accurately predict progression of vascular calcification, cardiovascular events and death. T50 is the only reliable test to individualize the treatment modality of kidney patient to improve prognosis.

CareAcross is a digital health company focusing on cancer patients, on a global scale.
It is already active in several large countries in 3 continents (Europe, Asia, Americas) including translations and localisation by custom native speakers.
We have been actively investigating the optimal path to China as a very interesting market, but also one that can benefit significantly from our services (both on the patient level, and the industry/academia/research level).

CarthaGenetics® provides consulting services to rare diseases, advanced therapies, and orphan drugs companies who want to step in the complex European markets (including Turkey) and the fast-growing North African markets. CarthaGenetics® was founded in 2004 by Philippe Carteron, on the basis of his personal commitment to the treatment of orphan diseases (rare & mostly genetic diseases) across Western Europe, Turkey & North Africa.
CarthaGenetics® has worked for the most prestigious biotech and pharma companies, as Alexion, Alnylam, Amicus, Biogen, BioMarin, FoldRX/Pfizer, Genzyme, Horizon, Insmed, Orchard, PTC, RegenXbio, Shire, Ultragenyx, as well as for Turkish Ministry of Health and Turkish Pharmacist Association (TEB). CarthaGenetics® is focused on innovative medicines, including cell and gene therapies and has 3 main areas of expertise:

1) Speed up the enrollment in Clinical Trial(s) through patient identification in cooperation with CROs:
- Our direct presence in countries with high birth numbers as Turkey, Algeria, Tunisia, Morocco is increasing the chances to complete enrollment in a shorter time.
- Our strong network among Pediatricians, Metabolicians, (Pediatric) Neurologists, Lipidologists, (Pediatric) Nephrologists, Geneticists, Hematologists and Oncologists will speed up patients identification.

2) Early Access Program (EAP or NPP) including Compassionate Use and Named Patient Sales (NPS) in countries where such programs are allowed as for instance:
- ATU in France
- Law 648 / Law 326 in Italy
- Endikasyon Dışı Kullanım Kılavuzu in Turkey

3) Biosimilars of Orphan Drugs for North Africa where there is no Orphan Drug exclusivity, representing a population about 100M. For any question please send us a message on contact@carthagenetics.com or contact us at our Swiss Headquarter +41 22 575 31 31 and visit our website at www.carthagenetics.com

CarthaGenetics® is directly present in Switzerland, France, Germany, Italy, Spain, Turkey as well as in Algeria and Tunisia

Cell4Pharma BV is a Dutch Bio-tech company that produces and commercializes human renal proximal tubule epithelial cell lines to perform in vitro toxicology assessments, with the aim to eliminate renal toxicity for compounds entering clinical stages of drug development; Cell4Pharma aims to lower drug failure during the clinical phase of drug development due to kidney toxicity.
To get more successful drugs to market, we empower researchers to accurately identify and eliminate nephro-toxic compounds during preclinical stages of drug development. We partner with CRO's to deliver our highly accurate and stable human renal ciPTEC Cell Lines to researchers of Bio-pharmaceutical companies and Academia

Cello Health BioConsulting, previously Defined Health, is a knowledge-based consultancy deeply rooted in science and the unique and ever-evolving challenges and opportunities facing the biopharma industry. We provide strategic advice for corporate growth strategy, disease area selection, indication prioritization, early market access strategy and early value profile development. Cello Health BioConsulting is known for “unconventional insight” – forward thinking, independent,
objective and actionable strategic advice to realize value across all therapeutic areas and stages of
development.